Cefodizime acid
cefodizime
CAS: 69739-16-8
Molecular Formula: C20H20N6O7S4
Cefodizime acid - Names and Identifiers
Cefodizime acid - Physico-chemical Properties
| Molecular Formula | C20H20N6O7S4 |
| Molar Mass | 584.67 |
| Density | 1.86±0.1 g/cm3(Predicted) |
| Melting Point | >170°C (dec.) |
| Specific Rotation(α) | D25 -55.9° |
| Solubility | DMSO (Slightly), Methanol (Slightly, Heated) |
| Appearance | Solid |
| Color | White to Off-White |
| pKa | pK1 2.85; pK2 3.37; pK3 4.18(at 25℃) |
| Storage Condition | -20°C Freezer |
| Refractive Index | 1.851 |
| Physical and Chemical Properties | [Α] D23-55.9 °. Pk12.85,Pk23.37,Pk34.18. UV absorption maximum (water):228,260,288nm (δ7800, 17800,15800). Cefodizime Sodium: C20H18N6O7S4Na2. [86329-79-5j. White to yellowish white crystalline powder, odorless or slightly specific odor, bitter taste. Very soluble in water (about 270g/L), a few insoluble in ethanol or ether. Acute toxicity LD50 mice and rabbits (mg/kg):4000~8000 intravenous injection. Acute toxicity LD50 rats (mg/kg):4000~8000 intravenous injection, 15000~17500 subcutaneous injection, 8000~11000 intraperitoneal injection. |
| Use | Content determination |
Cefodizime acid - Risk and Safety
| Hazard Symbols | Xi - Irritant |
| Risk Codes | R36/37/38 - Irritating to eyes, respiratory system and skin. R42/43 - May cause sensitization by inhalation and skin contact. |
| Safety Description | S22 - Do not breathe dust. S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection. |
Cefodizime acid - Reference Information
| Overview | Cefodizime (CDZ) the company developed a cephalosporin, the world's first immune enhancing function of the third generation cephalosporin, compared with other similar drugs, the product not only has a broad spectrum of antibacterial activity, it also has immune enhancing effect. Clinical mainly for Pneumonia of cocci, streptococcus and other sensitive bacteria caused by Pneumonia, bronchitis, tonsillitis, pyelonephritis, cholangitis, urinary tract infection, gonococcal urethritis, pharyngitis, cholecystitis, gynecological infections and otitis media. Now the research and application show that cefodizime for immunocompromised children and the elderly also have high clinical value. |
| pharmacological effect | This product has good antibacterial effect, and the killing effect of Borrelia berghei is significantly higher than that of ceftriaxone and minocycline. At the same time, Z can widely enhance the chemotaxis, phagocytosis and bactericidal function of phagocytic cells, and can enhance the oxidation reaction and respiratory burst related to the oxidation-dependent bactericidal system of phagocytic cells, at the same time, it has synergistic effect with non-oxygen-dependent bactericidal system, so as to enhance the phagocytic bactericidal effect of phagocytes; Significantly increase the number of CD cells in immunodeficient patients, and increase or return to normal CD4 /CD8 ratio; the activity of NK cells was significantly enhanced, and the expression of IL.2R in activated lymphocytes was increased. This product has the general third generation cephalosporin antibiotics with broad-spectrum antibacterial activity, for a variety of infections have a certain effect, but also has the general antibiotics do not have the immune enhancement effect, especially suitable for low immunity and liver and kidney dysfunction use. |
| antimicrobial spectrum | cefodizime is the third generation of parenteral cephalosporins. Cefodizime has a high affinity for proteins involved in cell wall synthesis in sensitive bacteria. Cefodizime has a broad antibacterial spectrum, including most of the clinically relevant Gram-positive bacteria, gram-negative bacteria, aerobic bacteria and oxygen pressure bacteria. Cefodizime is not sensitive to most β-lactamases, and cefodizime is effective in vitro against the following pathogens: Staphylococcus aureus (with the exception of neoblasts-resistant strains), Pneumonia streptococci, streptococci, neisseria gonorrhoeae (including penicillinase-producing strains), Neisseria meningitidis, Branhamlla, Escherichia coli, Shigella, salmonella, citrate, Klebsiella, proteus vulgaris, Proteus mirabilis, providenia, moiren's Morganella, Haemophilus influenzae, and Corynebacterium. The pathogenic bacteria with different sensitivity to cefodizime were coagulobacter, Enterobacter, epidermal glucose and bacillus. The bacteria that are not sensitive to cefodizime are Pseudomonas, Acinetobacter, Enterococcus faecalis, monocytic listeria, Mycoplasma and chlamydia. |
| pharmacokinetics | bioavailability and plasma concentration in healthy adults the mean maximum plasma concentration c of 1 g ~ 2 g single iv was 215 mg • L- 1~394 mg • L- 1, A dose-dependent relationship can be observed. im CDZ 1 g in adult healthy subjects after 1 h ~ 1.5 h reached the peak concentration of 60 mg • L- 1~75 mg • L- 1. In patients with acute exacerbation of chronic bronchitis, im 1 g or 2 g Cef, mean cmax values were 49,104 mg • L- 1, respectively. Distribution of protein binding: CDZ in the concentration of 12.5 mg • L- 1~100 mg • L- 1 in the range of serum protein binding rate was 81%, when the serum concentration was more than 100 mg · L- 1, the protein binding rate was significantly decreased. The elimination of CDZ is mainly excreted with the urine, and a small amount will be excreted from the bile. |
| indication | cefodizime has an enhanced immune response, in animal models and human in vitro and in vivo studies have shown that the drug can activate macrophages, improve their phagocytic activity and bactericidal rate. In vivo, cefodizime prolongs the survival of infected animals, including those infected with resistant bacteria or experimentally immunocompromised animals. Clinical mainly for Streptococcus, Pneumonia cocci and other sensitive bacteria caused by Pneumonia, bronchitis, pharyngitis, tonsillitis, pyelonephritis, urinary tract infection, gonococcal urethritis, cholecystitis, cholangitis, gynecological infections, sepsis and otitis media. |
| adverse reactions | may cause allergic rash, intestinal dysfunction, thrombocytopenia, leukopenia, eosinophilia, diarrhea and other adverse reactions. |
| precautions | should be used with caution for those allergic to penicillin or those with allergic constitution. |
| Main references | 1. Yu, Donghui et al. Antibacterial Activity, pharmacokinetics and clinical application of cefodizime [J]. Chinese Pharmaceutical Journal, 1998,5(33): 2. Zhang Qiang. Clinical Efficacy and safety evaluation of cefodizime in pediatric patients [J]. Chinese Journal of Hospital Pharmacy, 2009,29(15):1314 3. Wang Bin et al. Cefodizime increases the ratio of CD4 /CD8 and Th1 /Th2 cells in peripheral blood of Bacterial Pneumonia elderly patients [J]. Chin J Cell Mol Immunol,2015,31(4):528 4.http://baike.baidu.com/subview/96944/96944.htm#2 |
| Use | cefodizime is the third generation of broad-spectrum semi-synthetic cephalosporin antibiotics jointly developed by the German Herst company and the French Rosel company, mainly used for Pneumonia cocci, streptococcus and other sensitive bacteria caused by Pneumonia, acute and chronic bronchitis, gonococcal urethritis, mastitis, sepsis, cholangitis, cholecystitis, intrauterine infection, tonsillitis, pharyngitis peritonitis. |
| production method | Method 1: cefotaxime was used as raw material. 6.1g of (2-mercapto-4-methylthiazol-5-yl) acetic acid were dissolved in water and adjusted to pH 6.5 with 2mol/L sodium hydroxide. After heating to 70 °c, a solution of 12g of cefotaxime in 75ml of water was added with stirring. Stirring was continued for 3H at 70 °c and the pH was maintained at 6.5 by addition of 2mol/L sodium hydroxide. Cool to room temperature and acidify to Ph = 2.8. The filtered precipitate was washed with water and dried under vacuum in the presence of phosphorus pentoxide to give 10g of cefodizime. Method 2: 7-ACA was used as raw material. 10g of 7-ACA tosylate and 4.7g of (2-mercapto-4-methylthiazol-5-yl) acetic acid were suspended in 6.5 of water and pH was adjusted to 6.8-with 1mol/L sodium hydroxide. The mixture was stirred at 60 °c for 3H and the pH was maintained at 6.5-6.8. After cooling to room temperature, the reaction solution was shaken 3 times with ethyl acetate, and each time the ethyl acetate was discarded. The aqueous layer was acidified with 2mol/L hydrochloric acid to Ph = 4.0. The precipitate was removed by filtration and washed with water. The washings and filtrate were combined and stirred with 200ml of acetone. The precipitate was collected by filtration, washed with acetone and dried under vacuum to give 6.7g of compound (I). 7.54G of 2-(Z)-methoxyimino-2-(2-aminothiazol-4-yl) acetic acid was dissolved in 100ml of dimethylformamide and 5.7g of 1-hydroxybenzotriazole-hydrate (HOBT? H2O) and 8.5g of dicyclohexylcarbodiimide (DCCI) were stirred at room temperature for 4H, and the resulting dicyclohexylurea was removed by filtration. 15g of finely ground compound (I) was added and stirring was continued for 18h. The reaction solution was filtered, and then 380ml of water was added thereto. The precipitate was removed by filtration, and 450ml of water was further added to the filtrate. The crystals were collected by filtration and washed with water to give 6g of cefodizime. |
Last Update：2024-04-09 20:48:19
Supplier List
Spot supply
Product Name: Cefodizime Visit Supplier Webpage Request for quotationCAS: 69739-16-8
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Spot supply
Product Name: Cefodizime Visit Supplier Webpage Request for quotationCAS: 69739-16-8
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History